|
| 36136304 | Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy. | Clin Cancer Res | 2023 |
| 37716223 | Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival. | Gynecol Oncol | 2023 |
| 37102083 | Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine. | Gynecol Oncol Rep | 2023 |
| 36709663 | Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer. | Gynecol Oncol | 2023 |
| 34782936 | MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. | Virchows Arch | 2022 |
| 35380877 | The transcription factor PAX8 promotes angiogenesis in ovarian cancer through interaction with SOX17. | Sci Signal | 2022 |
| 35642517 | Homologous recombination deficiency and molecular subtype are associated with immunogenicity in ovarian cancer. | Biomark Med | 2022 |
| 35690498 | OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. | Gynecol Oncol | 2022 |
| 36075393 | NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022. | J Natl Compr Canc Netw | 2022 |
| 36104728 | Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors. | Diagn Pathol | 2022 |
| 36240472 | State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report. | JCO Precis Oncol | 2022 |
| 36222710 | Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes. | Clin Cancer Res | 2022 |
| 34645648 | Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study. | Clin Cancer Res | 2022 |
| 33229045 | Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition. | Gynecol Oncol | 2021 |
| 33545690 | Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2021 |
| 33537389 | PARPi after PARPi in epithelial ovarian cancer. | Gynecol Oncol Rep | 2021 |
| 33667670 | Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. | Ann Oncol | 2021 |
| 33752918 | Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. | Gynecol Oncol | 2021 |
| 33608192 | Image-Guided Percutaneous Thermal Ablation of Oligometastatic Ovarian and Non-Ovarian Gynecologic Tumors. | J Vasc Interv Radiol | 2021 |
| 34904811 | Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors. | Cancer J | 2021 |
| 34642026 | Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer. | Gynecol Oncol | 2021 |
| 33941784 | Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). | Nat Commun | 2021 |
| 34036138 | Treatment of metastatic placental site trophoblastic tumor with surgery, chemotherapy, immunotherapy and coil embolization of multiple pulmonary arteriovenous fistulate. | Gynecol Oncol Rep | 2021 |
| 32404957 | Association of PD-L1 expression by immunohistochemistry and gene microarray with molecular subtypes of ovarian tumors. | Mod Pathol | 2020 |
| 31815769 | Mechanisms of PARP inhibitor resistance in ovarian cancer. | Curr Opin Obstet Gynecol | 2020 |
| 31804230 | Biomarkers that may predict response to immunotherapy in ovarian malignancies. | Curr Opin Obstet Gynecol | 2020 |
| 32554541 | Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). | Clin Cancer Res | 2020 |
| 32473302 | Prognostic gene expression signature for high-grade serous ovarian cancer. | Ann Oncol | 2020 |
| 30571658 | Editorial: The potential for precision medicine to improve care and speed the development of new treatments in breast and gynecologic malignancies. | Curr Opin Obstet Gynecol | 2019 |
| 31257009 | Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy. | Gynecol Oncol | 2019 |
| 30922730 | Inhibition of PD-1 and VEGF in microsatellite-stable endometrial cancer. | Lancet Oncol | 2019 |
| 30979685 | Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer. | EBioMedicine | 2019 |
| 30765787 | Oncogenic Y68 frame shift mutation of PTEN represents a mechanism of docetaxel resistance in endometrial cancer cell lines. | Sci Rep | 2019 |
| 30425037 | BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. | Cancer Discov | 2019 |
| 29069370 | Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. | Ann Oncol | 2018 |
| 31799491 | <i>BRAF</i> Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition. | JCO Precis Oncol | 2018 |
| 29925470 | Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability. | Gynecol Oncol | 2018 |
| 29951943 | RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment. | Horm Cancer | 2018 |
| 30815151 | Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions. | AMIA Annu Symp Proc | 2018 |
| 30485824 | Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. | Cell Rep | 2018 |
| 29227302 | The target invites a foe: antibody-drug conjugates in gynecologic oncology. | Curr Opin Obstet Gynecol | 2018 |
| 27941363 | Cancer genomics and clinical practice: how can we close the gap more quickly? | Curr Opin Obstet Gynecol | 2017 |
| 28380314 | Understanding Exceptional Responses to Poly (ADP-ribose) Polymerase Inhibition in Sporadic Ovarian Cancer. | J Clin Oncol | 2017 |
| 28159814 | Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes. | Clin Cancer Res | 2017 |
| 28964622 | Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer. | Gynecol Oncol | 2017 |
| 28916367 | Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet | 2017 |
| 28882436 | Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. | Gynecol Oncol | 2017 |
| 27908594 | Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. | Lancet Oncol | 2017 |
| 27870704 | Clinical Outcomes for Stereotactic Ablative Radiotherapy in Oligometastatic and Oligoprogressive Gynecological Malignancies. | Int J Gynecol Cancer | 2017 |
| 28041631 | Targeting fibroblast growth factor pathways in endometrial cancer. | Curr Probl Cancer | 2017 |